U.S. markets closed

CryoLife, Inc. (CRY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
19.34+0.25 (+1.31%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close19.09
Open19.21
Bid19.34 x 800
Ask19.36 x 900
Day's Range19.06 - 19.37
52 Week Range12.63 - 31.77
Volume85,423
Avg. Volume277,553
Market Cap732.174M
Beta (5Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)-0.30
Earnings DateNov 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec 09, 2015
1y Target Est27.88
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-50% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • CryoLife Announces Release Date and Teleconference Call Details for 2020 Third Quarter Financial Results
    PR Newswire

    CryoLife Announces Release Date and Teleconference Call Details for 2020 Third Quarter Financial Results

    CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2020 third quarter financial results will be released on Wednesday, November 4, 2020 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.

  • CryoLife to Present at the 18th Annual Morgan Stanley Global Healthcare Conference
    PR Newswire

    CryoLife to Present at the 18th Annual Morgan Stanley Global Healthcare Conference

    CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming 18th Annual Morgan Stanley Global Healthcare Conference.

  • CryoLife Acquires Ascyrus Medical
    PR Newswire

    CryoLife Acquires Ascyrus Medical

    CryoLife, Inc. ("CryoLife"; NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has acquired Ascyrus Medical LLC (Ascyrus). Ascyrus is a Florida-based, privately-held developer of the Ascyrus Medical Dissection Stent (AMDS™), the world's first aortic arch remodeling device used for the treatment of acute Type A aortic dissections. The addition of the AMDS to CryoLife's product portfolio further strengthens the Company's position as a leader in the growing aortic repair market.